SRRK Scholar Rock Holding Corporation

9.63
-0.46  -5%
Previous Close 10.09
Open 10.1
Price To Book 2.35
Market Cap 285,803,204
Shares 29,678,422
Volume 37,837
Short Ratio
Av. Daily Volume 128,079
Stock charts supplied by TradingView

NewsSee all news

  1. Scholar Rock Provides Corporate Update and Outlines Key R&D Priorities for 2020

    - Completed enrollment of TOPAZ Phase 2 clinical trial of SRK-015 in patients with Type 2 and Type 3 Spinal Muscular Atrophy - Submitted IND application for SRK-181, a potent and selective inhibitor of latent TGFβ1

  2. Scholar Rock Achieves First Milestone in Strategic Fibrosis Collaboration with Gilead Sciences

    Successful demonstration of preclinical in vivo proof-of-concept studies advances collaboration to develop highly specific inhibitors of TGFβ activation for the potential treatment of patients suffering from fibrotic

  3. Scholar Rock Added to NASDAQ Biotechnology Index

    CAMBRIDGE, Mass., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ:SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth

  4. Scholar Rock Reports Preliminary Pharmacokinetic and Pharmacodynamic Data from TOPAZ Phase 2 Trial of SRK-015 for the Treatment of Patients with Spinal Muscular Atrophy

    Biomarker results confirm presence of latent myostatin in patients with SMA, further supporting relevance of drug target in diseaseSRK-015 demonstrated robust and dose-dependent target engagementData provide first

  5. Scholar Rock Reports Third Quarter 2019 Financial Results and Highlights Business Progress

    Enrollment on track in the TOPAZ Phase 2 clinical trial of SRK-015 in patients with Type 2 and Type 3 Spinal Muscular Atrophy for preliminary PK/PD results by year-endAccelerated initiation of Phase 1 dose escalation and

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 initial PK/PD data confirmed presence of latent myostatin in patients with SMA - November 19, 2019. Interim efficacy data 1H 2020 with top-line data 4Q 2020.
SRK-015 - TOPAZ
Spinal muscular atrophy (SMA
Phase 1 trial to be initiated 1Q 2020.
SRK-181
Solid Tumors

Latest News

  1. Scholar Rock Provides Corporate Update and Outlines Key R&D Priorities for 2020

    - Completed enrollment of TOPAZ Phase 2 clinical trial of SRK-015 in patients with Type 2 and Type 3 Spinal Muscular Atrophy - Submitted IND application for SRK-181, a potent and selective inhibitor of latent TGFβ1

  2. Scholar Rock Achieves First Milestone in Strategic Fibrosis Collaboration with Gilead Sciences

    Successful demonstration of preclinical in vivo proof-of-concept studies advances collaboration to develop highly specific inhibitors of TGFβ activation for the potential treatment of patients suffering from fibrotic

  3. Scholar Rock Added to NASDAQ Biotechnology Index

    CAMBRIDGE, Mass., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ:SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth

  4. Scholar Rock Reports Preliminary Pharmacokinetic and Pharmacodynamic Data from TOPAZ Phase 2 Trial of SRK-015 for the Treatment of Patients with Spinal Muscular Atrophy

    Biomarker results confirm presence of latent myostatin in patients with SMA, further supporting relevance of drug target in diseaseSRK-015 demonstrated robust and dose-dependent target engagementData provide first

  5. Scholar Rock Reports Third Quarter 2019 Financial Results and Highlights Business Progress

    Enrollment on track in the TOPAZ Phase 2 clinical trial of SRK-015 in patients with Type 2 and Type 3 Spinal Muscular Atrophy for preliminary PK/PD results by year-endAccelerated initiation of Phase 1 dose escalation and

  6. Scholar Rock to Present at the 2019 Jefferies London Healthcare Conference

    CAMBRIDGE, Mass., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ:SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth

  7. Scholar Rock to Present Preclinical and Phase 1 Clinical Data on SRK-015 at the World Muscle Society Congress

    CAMBRIDGE, Mass., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Scholar Rock (NASDAQ:SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental

  8. Scholar Rock to Present Preclinical and Phase 1 Clinical Data on SRK-015 at the World Muscle Society Congress

    CAMBRIDGE, Mass., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Scholar Rock (NASDAQ:SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental

  9. Scholar Rock Announces Appointment of George Nomikos, M.D., Ph.D., as Vice President, Head of Medical Research, Muscle Franchise

    CAMBRIDGE, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ:SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth

  10. Scholar Rock to Present at Upcoming Healthcare Conferences

    CAMBRIDGE, Mass., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ:SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth

  11. Scholar Rock Announces Upcoming Departure of Chief Financial Officer

    CAMBRIDGE, Mass., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ:SRRK), a clinical stage biopharmaceutical company, announced today that its Chief Financial Officer, Rhonda Chicko, will be